R. Dahl (Aarhus, Denmark), R. Pauwels (Ghent, Belgium)
Changes in airway inflammation, remodelling and PD20 following inhaled corticosteroid treatment are not temporally concordant
C. Ward, R. Bish, M. Pais, D. Reid, E. H. Walters (Tyne and Wear, United Kingdom; Melbourne, Tasmania, Australia)
|  |
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
D. Ediger, E. K. Uzaslan, E. G. Yuksel, F. Coskun, N. Ozyardimci, E. Ege (Bursa, Turkey)
| |
Nasal fibroblast functions involved in airway inflammation and remodelling are downregulated by fluticasone propionate (FP)
M. Silvestri, F. Sabatini, R. Sale, G. Dasic, G. A. Rossi (Genoa, Verona, Italy)
| |
Preclinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide
D. S. Bundschuh, D. Marx, A. Hatzelmann, R. Beume, D. Haefner, G. Hochhaus, F. Montoro, R. Riedel, M. Stoeck (Konstanz, Germany; Gainesville, United States Of America; Madrid, Spain)
| |
Pharmacokinetic factors affecting airway selectivity of inhaled steroids - role of intracellular esterification
S. Edsbacker, C. J. Johansson (Lund, Sweden)
| |
Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients
E. Derom, V. Van De Velde, S. Marissens, W. Vincken, R. A. Pauwels (Ghent, Brussels, Belgium)
| |
Pharmacokinetic (PK) and pharmacodynamic (PD) data for inhaled and intranasal corticosteroids (CS) reassessed using a physiological PK/PD model
P. T. Daley-Yates, L. N. Pierre (Greenford, United Kingdom)
| |
Mometasone furoate is safe and effective for long-term use in patients with mild-to-moderate persistent asthma
A. S. Nayak, K. L. Lampl, N. Segall, J. E. Harrison, C96-136 Study Group (Normal, Rockville, Atlanta, Kenilworth, United States Of America)
| |